AGC Biologics announced that it will construct a new manufacturing facility for biologics and advanced therapy medicinal products (ATMPs) in Yokohama Japan. It expects the site to be operational in 2026.
The 20,000 m² facility will offer pre-clinical through to commercial services for mammalian-based protein biologics, messenger RNA (mRNA) and cell therapy services.
In 2021, AGC Biologics and Xbrane Biopharma entered into an agreement to manufacture Xcimzane™ (certolizumab pegol) for clinical development.